Compare PLNT & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLNT | CORT |
|---|---|---|
| Founded | 1992 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 7.6B |
| IPO Year | 2015 | N/A |
| Metric | PLNT | CORT |
|---|---|---|
| Price | $109.54 | $87.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | $118.77 | ★ $139.00 |
| AVG Volume (30 Days) | ★ 1.2M | 690.9K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.23 | N/A |
| EPS | ★ 2.44 | 0.87 |
| Revenue | ★ $1,202,700,000.00 | $741,172,000.00 |
| Revenue This Year | $21.34 | $23.79 |
| Revenue Next Year | $11.14 | $40.97 |
| P/E Ratio | ★ $44.50 | $100.74 |
| Revenue Growth | 14.63 | ★ 17.92 |
| 52 Week Low | $87.72 | $49.00 |
| 52 Week High | $114.47 | $117.33 |
| Indicator | PLNT | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 58.67 | 67.59 |
| Support Level | $106.66 | $81.31 |
| Resistance Level | $109.98 | $87.19 |
| Average True Range (ATR) | 2.40 | 2.87 |
| MACD | -0.44 | 0.69 |
| Stochastic Oscillator | 47.02 | 88.95 |
Planet Fitness Inc is a franchisor and operator of fitness centers in the United States. The company's reportable segments are Franchise, Corporate-owned stores, and Equipment. Franchise segment includes operations related to its franchising business in the United States, Puerto Rico, Canada, Panama, Mexico and Australia, Corporate-owned stores segment includes operations with respect to all corporate-owned stores throughout the United States and Canada, and The Equipment segment includes the sale of equipment to franchisee-owned stores in the U.S. The firm generates a majority of its revenue from the Corporate-owned stores segment.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.